Abstract:Since its emergence in the late 1980s, nanotechnology has shown vast potential in biological medicine fields, including drug delivery, diagnostics, and tissue regeneration [1]. Owing to the enhanced permeability and retention (EPR) effect of solid tumors discovered over 30 years ago [2], nanomedicines have mostly been developed for cancer diagnosis and therapy, and few of them have been applied clinically [3]. Despite the long-standing debate on the existence of the EPR effect in human patients [4], clinical outcomes have shown that nanomedicines reduce the systemic toxicity and adverse effects of therapeutic agents by altering their pharmacokinetics and biodistributions [5]. Beyond the applications for cancer, other applications are emerging in nanomedicines for metabolic, cardiovascular, and infectious diseases [6]. With the development and successful application of mRNA-lipid nanoparticle COVID-19 vaccines [7], unprecedented attention has been paid to the bench-to-bedside translation of nanomedicines worldwide. More than 500 ongoing and planned clinical trials in January 2023 were found using the search term "nanoparticle" on the ClinicalTrials.gov website (https://clinicaltrials.gov/). China is also accelerating its pace of nanomedicine translation, and the CFDA has approved seven products for clinical uses in the past 3 years. This special issue compiles eight review articles that discuss recent progress and future directions in nanomedicines to promote their bench-to-bedside translation. Lipid nanoparticles (LNPs) have provided valuable platforms for various therapeutics, from liposomal drugs applied in clinics to cationic lipid nanoparticles that enable mRNA vaccine delivery; thus, LNPs will continue to be a research hot spot in nanomedicine translation [8]. Liposomes and cationic lipid-nucleic acid complexes have received attention. Solid LNPs (SLNPs) have also attracted attention, owing to their ease of preparation, physicochemical stability, and scalability. These characteristics enable the large-scale production of SLNPs; however, some challenges must be resolved in future industrial manufacturing, such as polymorphism, phase separation, and sterilization resulting from manufacturing processes [9]. Polymeric nanomedicines, including polymeric nanoparticles, micelles, and polymersomes, have many advantages for cancer therapy, such as a solubilizing ability for hydrophobic drugs, significant drug-sustained release, reduced drug toxicity, and enhanced drug accumulation in tumors [10]. To enhance the in vivo therapeutic efficacy, various multifunctional nanomedicines have been reported, for example, spontaneous property transitions in response to endogenous and/or exogenous stimuli (e.g., pH, temperature, light, ultrasound, redox, and enzyme) for specific delivery. However, these nanomedicines usually have sophisticated structures, causing difficulties in large-scale production, in vivo characterization, and clinical translation. In the review article "'One-for-All' approach: a black technology for nanomedicine development", Youqing Shen et al. provide a promising strategy of "One-for-All", in which the polymeric nanocarrier prepared from phospholipid-affinitive poly (tertiary amine-oxide) has a simple structure but enables all the properties necessary for an in vivo delivery process. Because the tumor microenvironment (TME) plays an important role in cancer procession and metastasis, modulating the TME has been an alternate cancer treatment strategy, offering reduced toxicity and enhancing other cancer therapies [11, 12]. Polymeric nanomedicines have substantial potential in remodeling the TME, owing to their controlled synthesis, high modifiability, and tunable responses to various stimuli [13]. The review article "Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy", by Xuesi Chen et al. provides an overview of the applications of stimuli responsive polymeric nanomedicines for remodeling the TME and contributes valuable insights and strategies for developing the next generation of polymeric nanomedicines in personalized and precise cancer therapy. Inspired by the natural merits of biocomponents, biomimetic approaches to improve the in vivo properties of nanomedicines, such as prolonged blood circulation, reduced immunogenicity, specific delivery, and reduced toxicity, have been reported in the literature. Abraxane (albumin-bound paclitaxel) is an example of a biomimetic nanomedicine approved by the FDA for first-line cancer therapy. Utilizing the innate ability of albumin to bind hydrophobic molecules, Abraxane was shown to enhance the therapeutic efficacy and reduce the unwanted side effects of paclitaxel [14]. Low-density lipoprotein (LDL), endogenous lipid nanoparticles responsible for cholesterol transport, is an ideal biomimetic nanocarrier -Abstract Truncated-

Therapeutic Copolymer from Salicylic Acid and l-Phenylalanine as a Nanosized Drug Carrier for Orthotopic Breast Cancer with Lung Metastasis

Self-assembled polymer nanostructures for delivery of anticancer therapeutics

Breast tumor‐targeted drug delivery via polymer nanocarriers: Endogenous and exogenous strategies

Polymeric nanoparticles-Promising carriers for cancer therapy

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression.

Redox-responsive Nanomicelles with Intracellular Targeting and Programmable Drug Release for Targeted Tumor Therapy

Exploring the Frontier of Biopolymer-Assisted Drug Delivery: Advancements, Clinical Applications, and Future Perspectives in Cancer Nanomedicine

Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges

Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks

Fluorinated Organic Polymers for Cancer Drug Delivery

Polymer-Based Cancer Nanotheranostics: Retrospectives of Multi-Functionalities and Pharmacokinetics

Functional polymeric core–shell hybrid nanoparticles overcome intestinal barriers and inhibit breast cancer metastasis

Construction of Amphiphilic Copolymer Nanoparticles Based on Hyperbranched Poly (Amine-Ester) and 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine As Drug Carriers for Cancer Therapy.

Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer

Drug Delivery: Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier-Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor (Adv. Funct. Mater. 35/2014)

Promoting the bench-to-bedside translation of nanomedicines

Biosynthetic and Unfolded Protein Nanocarriers for Chemotherapeutic Drugs in Oral Cancers: Improved Bioavailability and Safety of Chemotherapeutics

Advancements in Cancer Therapeutics: Current Paradigms in Applying Biodegradable Polymer Nanoparticles for Enhanced Management

Rational Design of Synthetic Polymers As Drug Carriers for Cancer Therapy

Poly(phenylalanine) and poly(3,4-dihydroxy-L-phenylalanine): Promising biomedical materials for building stimuli-responsive nanocarriers